Works matching IS 00099104 AND DT 2023 AND VI 214 AND IP 2
Results: 9
Leucine-rich repeat kinase 2 promotes the development of experimental severe acute pancreatitis.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 182, doi. 10.1093/cei/uxad106
- By:
- Publication type:
- Article
Increased thromboinflammatory load in hereditary angioedema.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 170, doi. 10.1093/cei/uxad091
- By:
- Publication type:
- Article
The CXCL12-CXCR4-NLRP3 axis promotes Schwann cell pyroptosis and sciatic nerve demyelination in rats.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 219, doi. 10.1093/cei/uxad081
- By:
- Publication type:
- Article
Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 209, doi. 10.1093/cei/uxad088
- By:
- Publication type:
- Article
Alpha-ketoglutarate supplementation reduces inflammation and thrombosis in type 2 diabetes by suppressing leukocyte and platelet activation.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 197, doi. 10.1093/cei/uxad086
- By:
- Publication type:
- Article
Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 162, doi. 10.1093/cei/uxad105
- By:
- Publication type:
- Article
Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 154, doi. 10.1093/cei/uxad108
- By:
- Publication type:
- Article
MAIT cells in bacterial infectious diseases: heroes, villains, or both?
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 144, doi. 10.1093/cei/uxad102
- By:
- Publication type:
- Article
Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 2, p. 131, doi. 10.1093/cei/uxad083
- By:
- Publication type:
- Article